Core Viewpoint - Meigen Gene (06667) reported a revenue of approximately 164 million yuan for 2024, representing a year-on-year growth of 8.5% and a net profit of 45 million yuan, which is a 50.0% increase compared to the previous year [1] Group 1 - The company achieved earnings per share of 0.22 yuan [1] - The growth in revenue and net profit is attributed to the company's commitment to product design innovation and continuous enhancement of its product matrix and structure [1] - The company has adopted an active market expansion strategy, exploring more sales scenarios and channels to tap into potential market demand and sales opportunities [1] Group 2 - The establishment of a diversified sales system has further improved customer service experience, contributing to steady growth in revenue and net profit [1]
美因基因公布2024年业绩 实现净利润4500万元 同比增长50.0%